Sestre Milosrdnice University hospital and Institute of Clinical Medical Research
Abstract
The effectiveness of homocysteine-lowering therapy on stroke prevention is still unclear. Although randomized controlled epidemiological trials have yielded mixed findings, a multicenter trial did not show any beneficial effect. Genetic studies are still lacking. Therefore, we report on a female patient with transient ischemic attacks and the thermolabile variant of methylenetetrahydrofolate reductase (TT genotype), who benefited from supplemental therapy for homocysteine lowering.Učinkovitost terapije snižavanja homocisteina u prevenciji moždanog udara ostaje nejasnom. Iako su randomizirana kontrolirana epidemiološka ispitivanja polučila mješovite nalaze, jedna multicentrična studija nije pokazala nikakav koristan učinak, dok genetičke studije još uvijek nedostaju. Prikazuje se slučaj bolesnice s prolaznim ishemijskim napadajima i termolabilnom varijantom metilen-tetrahidrofolat reduktaze (TT genotip) u koje se terapija dodacima hrani radi snižavanja homocisteina pokazala korisnom
